Evidence map›Paper›PMID 41410809›Full record

ArticleClinical and experimental nephrology2026

Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations.

Nanaka Katsurayama, Hiroki Ishihara, Toshihito Hirai, Ayaka Saito, Daigo Okada, Kohei Unagami, Hironori Fukuda, Kazuhiko Yoshida, Kazuya Omoto, Junpei Iizuka and 4 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nanaka KatsurayamaDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kouhoku, Adachi-Ku, Tokyo, Japan.
Hiroki IshiharaDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan. ishihara.hiroki@twmu.ac.jp.ORCID http://orcid.org/0000-0002-5146-656X
Toshihito HiraiDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
Ayaka SaitoDepartment of Organ Transplant Medicine, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
Daigo OkadaDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
Kohei UnagamiDepartment of Organ Transplant Medicine, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
Hironori FukudaDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
Kazuhiko YoshidaDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
Kazuya OmotoDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
Junpei IizukaDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
Tomokazu ShimizuDepartment of Organ Transplant Medicine, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
Tsunenori KondoDepartment of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kouhoku, Adachi-Ku, Tokyo, Japan.
Hideki IshidaDepartment of Organ Transplant Medicine, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.
Toshio TakagiDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData regarding clinical outcomes of systemic therapy, including tyrosine kinase inhibitors (TKIs), for advanced renal cell carcinoma (RCC) after kidney transplantation (KTx) are limited.

methodsWe assessed clinical data of 13 patients with advanced RCC after KTx (KTx-RCC) who received first-line TKI monotherapy. Outcomes of the KTx-RCC group were compared with those of 275 patients with sporadic RCC and 37 patients receiving maintenance dialysis therapy for end-stage renal disease (ESRD) who received first-line TKIs.

resultsOverall survival (OS) was shorter in the KTx-RCC group than in the sporadic RCC group (p = 0.0007). However, multivariate analysis showed that the population type (i.e., KTx-RCC vs. sporadic RCC) was not an independent factor (p > 0.05). In contrast, other covariates such as non-clear cell histology (p = 0.0215), poor IMDC risk (p = 0.0304), and liver metastasis (p = 0.0016), which were frequently observed in the KTx-RCC group, were independent factors for shorter OS. Progression-free survival and OS were not significantly different between the KTx-RCC and ESRD-RCC groups (p > 0.05). Of the 13 patients in the KTx-RCC group, everolimus was administered to six patients (46%), but survival was not significantly different based on the administration (p > 0.05).

conclusionsThe survival of patients with KTx-RCC after TKI monotherapy was shorter than that of patients with sporadic RCC, possibly due to the presence of multiple poor prognosticators. Effective treatment strategies, including postoperative monitoring for early diagnosis, should be identified in this high-risk population.

Indexed as

Carcinoma, Renal CellKidney Failure, ChronicKidney NeoplasmsKidney TransplantationProtein Kinase InhibitorsAdultAgedFemaleHumansMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeProtein Kinase InhibitorsTyrosine Kinase InhibitorsHemodialysisImmune checkpoint inhibitorImmunotherapyKidney cancerMetastatic renal cell carcinoma

Identifiers

PMID41410809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.